A metabolomics/peptidomics and genomics
approach, using UPLC-MSE, molecular networking, and genome
mining, was used to describe
the serrawettin W2 lipopeptide family produced by Serratia
marcescens NP2. Seven known serrawettin W2 analogues
were structurally elucidated along with 17 new analogues, which varied
based on the first (fatty acyl length of C8, C10, C12, or C12:1), fifth (Phe, Tyr, Trp, or
Leu/Ile), and sixth (Leu, Ile, or Val) residues. Tandem MS results
suggested that the previously classified serrawettin W3 may be an
analogue of serrawettin W2, with a putative structure of cyclo(C10H18O2-Leu-Ser-Thr-Leu/Ile-Val). Chiral
phase amino acid analysis enabled the distinction between l/d-Leu and l-Ile residues within nine purified
compounds. 1H and 13C NMR analyses confirmed
the structures of four purified new analogues. Additionally, genome
mining was conducted using Serratia genome sequences available on the NCBI database to identify the swrA gene using the antiSMASH software. NRPSpredictor2 predicted
the specificity score of the adenylation-domain within swrA with 100% for the first, second, and third modules (Leu-Ser-Thr),
60–70% for the fourth module (Phe/Trp/Tyr/Val), and 70% for
the fifth module (Val/Leu/Ile), confirming MSE data. Finally,
antibacterial activity was observed for compounds 6 and 11 against a clinical Enterococcus faecium strain.